Phase 2 Colorectal Cancer Trial, Recruiting NCT07562503 Sponsor: Fudan University Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 2 Colorectal Cancer Trial, Recruiting

NCT07562503
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older, of any sex
  • People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard oncology scale (ECOG score of 0–2), with a life expectancy of more than 3 months
  • People who have been diagnosed through laboratory testing with high-risk stage II colorectal cancer after surgery, confirmed by tissue analysis
  • People whose blood test for circulating tumour DNA (ctDNA — tiny fragments of cancer-related genetic material in the blood) came back positive approximately one month after surgery
  • People with a life expectancy of more than 12 months
  • People who are able to understand and sign a consent form agreeing to take part, either personally or through a legal guardian or representative

Who may not be able to join:

  • People who received treatment (such as chemotherapy or radiation) before their surgery
  • People who had a blood transfusion during surgery or in the two weeks before surgery
  • People who are pregnant or breastfeeding, or people capable of having children who are not using adequate contraception
  • People who have had another type of cancer in the past 5 years, with the exception of certain treated skin cancers or early-stage cervical cancer that has been adequately treated
  • People with uncontrolled brain tumours or cancer that has spread to the brain or nervous system, or who have significant pressure in the brain or serious neurological or psychiatric symptoms
  • People with severe or uncontrolled ongoing health conditions, including: serious heart problems within the past 6 months (such as heart attack, heart failure, unstable chest pain, fluid around the heart, or dangerous irregular heartbeat); diagnosed neurological or psychiatric conditions such as dementia or seizure disorders; severe or uncontrolled infections; active blood clotting disorders or significant bleeding problems; or significant loss of function in major organs
  • People who, for any other reason, the trial doctors consider unsuitable for participation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-18017312703

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 November 2024
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Patient's 2-year Progression-Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov